Transcriptome analysis reveals key genes modulated by ALK5 inhibition in a bleomycin model of systemic sclerosis.

Decato, Benjamin E; Ammar, Ron; Reinke-Breen, Lauren; Thompson, John R; Azzara, Anthony V

Decato, Benjamin E; Ammar, Ron; Reinke-Breen, Lauren; Thompson, John R; Azzara, Anthony V.

Affiliation

Decato BE; Research & Early Development, Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.
Ammar R; Research & Early Development, Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.
Reinke-Breen L; Research & Early Development, Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.
Thompson JR; Research & Early Development, Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.
Azzara AV; Research & Early Development, Bristol-Myers Squibb Company, Lawrenceville, NJ, USA.

Rheumatology (Oxford) ; 61(4): 1717-1727, 2022 04 11.

Article in En | MEDLINE | ID: mdl-34289031

Subject(s)

Bleomycin; Scleroderma, Systemic; Animals; Disease Models, Animal; Fibroblasts/metabolism; Fibrosis; Gene Expression Profiling; Humans; Lung/pathology; Mice; Scleroderma, Systemic/chemically induced; Scleroderma, Systemic/genetics; Scleroderma, Systemic/metabolism; Skin/pathology

Key words

ALK5 inhibitor; RNA-seq; bleomycin; fibrosis; scleroderma; systemic sclerosis

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Scleroderma, Systemic / Bleomycin Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2022 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google